283 related articles for article (PubMed ID: 31708481)
21. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
22. Evolution of Hepatitis B Virus (HBV) Serologic Markers Among Antiretroviral-Naive Young People Living With Human Immunodeficiency Virus Who Had Undergone Neonatal HBV Vaccination and Initiated Antiretroviral Therapy.
Huang YC; Sun HY; Sheng WH; Hsieh SM; Huang SH; Chen GJ; Liu WD; Chang SY; Su YC; Su LH; Liu WC; Hung CC
Clin Infect Dis; 2022 Sep; 75(5):882-889. PubMed ID: 34893815
[TBL] [Abstract][Full Text] [Related]
23. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
24. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
He Y; Lin W; Li H; Gu F; Zhong H; Lan Y; Li Y; Guo P; Hu F; Cai W; Tang X; Li L
Chin Med J (Engl); 2023 Nov; 136(22):2686-2693. PubMed ID: 37881959
[TBL] [Abstract][Full Text] [Related]
25. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
[TBL] [Abstract][Full Text] [Related]
26. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination.
Sun HY; Ko WC; Tsai JJ; Lee HC; Liu CE; Wong WW; Su SC; Ho MW; Cheng SH; Yang CH; Lin YH; Miao WJ; Sheng WH; Hung CC
Am J Gastroenterol; 2009 Apr; 104(4):877-84. PubMed ID: 19259078
[TBL] [Abstract][Full Text] [Related]
28. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Mendes-Correa MC; Pinho JR; Gomes-Gouvea MS; da Silva AC; Guastini CF; Martins LG; Leite AG; Silva MH; Gianini RJ; Uip DE
BMC Infect Dis; 2011 Sep; 11():247. PubMed ID: 21933423
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
30. High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.
Rusine J; Ondoa P; Asiimwe-Kateera B; Boer KR; Uwimana JM; Mukabayire O; Zaaijer H; Mugabekazi J; Reiss P; van de Wijgert JH
PLoS One; 2013; 8(5):e63303. PubMed ID: 23717409
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand.
Peters PJ; McNicholl JM; Raengsakulrach B; Wasinrapee P; Mueanpai F; Ratanasuwan W; Intalapaporn P; Drobeniuc J; Ramachandran S; Thai H; Xia GL; Kamili S; Khudyakov Y; Weidle PJ; Teo CG; McConnell MS
J Int Assoc Provid AIDS Care; 2013; 12(5):349-53. PubMed ID: 23792710
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.
Ocama P; Seremba E; Apica B; Opio K
Afr Health Sci; 2015 Jun; 15(2):328-33. PubMed ID: 26124776
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B and C viral coinfections and their association with HIV viral load suppression among HIV-1 infected patients on ART at Mekelle hospital, northern Ethiopia.
Teame G; Gebreyesus A; Tsegay E; Gebretsadik M; Adane K
AIDS Res Ther; 2022 Dec; 19(1):57. PubMed ID: 36457041
[TBL] [Abstract][Full Text] [Related]
34. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
[TBL] [Abstract][Full Text] [Related]
35. HBV or HCV Coinfection in HIV-1-Infected Pregnant Women in France: Prevalence and Pregnancy Outcomes.
Benhammou V; Tubiana R; Matheron S; Sellier P; Mandelbrot L; Chenadec JL; Marel E; Khoshnood B; Warszawski J;
J Acquir Immune Defic Syndr; 2018 Apr; 77(5):439-450. PubMed ID: 29287028
[TBL] [Abstract][Full Text] [Related]
36. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Price H; Dunn D; Pillay D; Bani-Sadr F; de Vries-Sluijs T; Jain MK; Kuzushita N; Mauss S; Núñez M; Nüesch R; Peters M; Reiberger T; Stephan C; Tan L; Gilson R
PLoS One; 2013; 8(7):e68152. PubMed ID: 23874527
[TBL] [Abstract][Full Text] [Related]
37. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
Gantner P; Cotte L; Allavena C; Bani-Sadr F; Huleux T; Duvivier C; Valantin MA; Jacomet C; Joly V; Chéret A; Pugliese P; Delobel P; Cabié A; Rey D;
PLoS One; 2019; 14(4):e0215464. PubMed ID: 30998789
[TBL] [Abstract][Full Text] [Related]
38. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
39. Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.
Shilaih M; Marzel A; Scherrer AU; Braun DL; Kovari H; Rougemont M; Darling K; Battegay M; Hoffmann M; Bernasconi E; Hirzel C; Günthard HF; Kouyos RD; ;
J Infect Dis; 2016 Aug; 214(4):599-606. PubMed ID: 27190182
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
Otegbayo JA; Taiwo BO; Akingbola TS; Odaibo GN; Adedapo KS; Penugonda S; Adewole IF; Olaleye DO; Murphy R; Kanki P
Ann Hepatol; 2008; 7(2):152-6. PubMed ID: 18626434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
